Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

NCT04163874 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes
Type 1 Diabetes Mellitus
Hyperglycemia, Postprandial

Interventions

DRUG: Fiasp
DRUG: Pramlintide Acetate
DRUG: Placebo
DEVICE: Artificial Pancreas

Sponsor

McGill University

Collaborators

[object Object]